
Nasdaq: ARWRArrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Q4 FY2026 Results: Net Loss $724 Million on Revenue of $451 Million
Arrowhead Pharmaceuticals (Nasdaq: ARWR) reported results for its 2026 fiscal year ended 30 Sep 2026, with GAAP revenue of $450.8 million and a GAAP net loss attributable to the company of $724.2 million, it said on 12 Nov 2026. Diluted loss per share (GAAP) was $5.11. The release gives no adjusted (non-GAAP) figures.
- US stocks
- Earnings